



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**CONDENSED CONSOLIDATED INCOME STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2008**

	Note	3 MONTHS ENDED		PERIOD ENDED	
		30/09/2008	30/09/2007	30/09/2008	30/09/2007
		RM'000	RM'000	RM'000	RM'000
<b>Revenue</b>	11	<b>67,425</b>	<b>57,742</b>	<b>193,827</b>	<b>178,596</b>
Cost of sales		(51,352)	(44,169)	(147,168)	(136,700)
<b>Gross profit</b>		<b>16,073</b>	<b>13,573</b>	<b>46,659</b>	<b>41,896</b>
Other income		280	336	733	989
Selling & marketing expenses		(8,547)	(6,973)	(24,599)	(21,687)
Administrative expenses		(3,137)	(2,897)	(8,951)	(8,431)
Other expenses		(159)	(105)	(344)	(328)
Deferred gain on previously disposed subsidiary		-	-	-	1,825
Finance cost		(251)	(128)	(753)	(470)
Share of results of associates		821	448	1,573	938
<b>Profit before tax</b>	11	<b>5,080</b>	<b>4,254</b>	<b>14,318</b>	<b>14,732</b>
Income tax expense	23	(1,003)	(333)	(3,052)	(2,294)
<b>Net profit for the year</b>		<b>4,077</b>	<b>3,921</b>	<b>11,266</b>	<b>12,438</b>
<b>Attributable to:</b>					
Equity holders of the parent		3,954	3,921	11,143	12,438
Minority interest		123	-	123	-
		<b>4,077</b>	<b>3,921</b>	<b>11,266</b>	<b>12,438</b>
<b>Earnings per share attributable to equity holders of the parent:</b>					
		<u>Sen</u>	<u>Sen</u>	<u>Sen</u>	<u>Sen</u>
- Basic	31	<b>5.27</b>	<b>5.23</b>	<b>14.86</b>	<b>16.59</b>
- Diluted	31	<b>5.27</b>	<b>5.23</b>	<b>14.86</b>	<b>16.59</b>

The Condensed Consolidated Income Statements should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2007 and the accompanying explanatory notes attached to the interim financial report.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**CONDENSED CONSOLIDATED BALANCE SHEETS AS AT 30 SEPTEMBER 2008**

		<u>As at</u> <b>30/09/2008</b> <b>RM'000</b>	<u>Audited</u> <u>As at</u> <b>31/12/2007</b> <b>RM'000</b> <b>(Restated)</b>
<b>Non-Current Assets</b>			
Property, plant and equipment	12	57,633	62,708
Investment properties		7,690	3,900
Prepaid land lease payments		7,056	7,117
Intangible assets		1,529	1,626
Investment in associates		27,245	15,335
		<u>101,153</u>	<u>90,686</u>
<b>Current Assets</b>			
Inventories		42,323	40,575
Trade and other receivables		69,538	62,584
Deposits, bank and cash balances		12,050	11,676
		<u>123,911</u>	<u>114,835</u>
<b>TOTAL ASSETS</b>		<u><b>225,064</b></u>	<u><b>205,521</b></u>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity attributable to equity holders of the parent</b>			
Share capital		74,974	74,974
Reserves		9,278	9,067
Retained earnings	2 & 3	54,713	51,810
		<u>138,965</u>	<u>135,851</u>
<b>Minority interest</b>		5,500	-
<b>TOTAL EQUITY</b>		<u><b>144,465</b></u>	<u><b>135,851</b></u>
<b>Non-Current Liabilities</b>			
Borrowings	27	12,914	14,633
Deferred tax liabilities	2 & 3	2,477	1,987
		<u>15,391</u>	<u>16,620</u>
<b>Current Liabilities</b>			
Borrowings	27	7,431	10,848
Trade and other payables		54,038	41,932
Current tax payable		965	270
Dividend payable		2,774	-
		<u>65,208</u>	<u>53,050</u>
<b>TOTAL LIABILITIES</b>		<u><b>80,599</b></u>	<u><b>69,670</b></u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u><b>225,064</b></u>	<u><b>205,521</b></u>
		<u><b>RM</b></u>	<u><b>RM</b></u>
<b>Net Assets per share attributable to ordinary equity holders of the parent</b>		<u><b>1.85</b></u>	<u><b>1.81</b></u>

The Condensed Consolidated Balance Sheets should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2007 and the accompanying explanatory notes attached to the interim financial report.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008**

**(THE FIGURES HAVE NOT BEEN AUDITED)**

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 SEPTEMBER 2008**

	Note	Share Capital RM'000	Non-Distributable Share Premium RM'000	Revaluation & other reserves RM'000	Distributable Retained Profits RM'000	Total RM'000
<b><u>PERIOD ENDED 30 SEPTEMBER 2008</u></b>						
Balance as at 1 January 2008						
As previously stated		74,974	5,306	3,761	49,490	133,531
Effects of adopting FRS 112	2 & 3				2,320	2,320
As restated		74,974	5,306	3,761	51,810	135,851
Foreign currency translation, representing amount recognised directly in equity		-	-	211	-	211
Share of net assets to Minority Interest in excess of amount invested recognised directly in equity					(2,092)	(2,092)
Net profit for the 9-months period		-	-	-	11,143	11,143
Total recognised income and expense for the period		-	-	211	9,051	9,262
Dividends	10	-	-	-	(6,148)	(6,148)
<b>Balance as at 30 September 2008</b>		<b>74,974</b>	<b>5,306</b>	<b>3,972</b>	<b>54,713</b>	<b>138,965</b>
<b><u>PERIOD ENDED 30 SEPTEMBER 2007</u></b>						
Balance as at 1 January 2007		74,974	5,306	3,780	38,312	122,372
Foreign currency translation, representing amount recognised directly in equity		-	-	(28)	-	(28)
Net profit for the 9-months period		-	-	-	12,438	12,438
Total recognised income and expense for the period		-	-	(28)	12,438	12,410
Dividends	10	-	-	-	(5,735)	(5,735)
<b>Balance as at 30 September 2007</b>		<b>74,974</b>	<b>5,306</b>	<b>3,752</b>	<b>45,015</b>	<b>129,047</b>

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2007 and the accompanying explanatory notes attached to the interim financial report.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008**

**(THE FIGURES HAVE NOT BEEN AUDITED)**

**CONDENSED CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER 2008**

	PERIOD ENDED	
	30/09/2008	30/09/2007
	RM'000	RM'000
<b>Cash flows from operating activities</b>		
Profit before tax	14,318	14,732
Adjustments:		
Depreciation and amortization	4,676	3,566
Net profit on disposal of property, plant and equipment	(41)	(201)
Deferred gain on previously disposed subsidiary	-	(1,825)
Share of results of associates	(1,573)	(938)
Other non-cash items	1,762	2,665
Operating profit before working capital changes:	19,142	17,999
Inventories and receivables	(9,880)	(342)
Payables	12,106	1,043
Cash generated from operations	21,368	18,700
Tax paid	(1,813)	(1,922)
<b>Net cash generated from operating activities</b>	<b>19,555</b>	<b>16,778</b>
<b>Cash flows from investing activities</b>		
Acquisition of associate paid in cash	(7,052)	(3,870)
Proceeds from previously disposed subsidiary company	-	1,145
Purchase of property, plant and equipment & intangible assets	(3,113)	(16,057)
Proceeds from disposal of property, plant and equipment	104	267
Interest received	114	98
<b>Net cash used in investing activities</b>	<b>(9,947)</b>	<b>(18,417)</b>
<b>Cash flows from financing activities:</b>		
Term loans (repaid)/raised	(2,814)	10,010
Dividends paid	(3,374)	(2,737)
Other financing activities paid	1,076	(5,995)
<b>Net cash (used)/generated in financing activities</b>	<b>(5,112)</b>	<b>1,278</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>4,496</b>	<b>(361)</b>
<b>Cash and cash equivalents at the beginning of the financial year</b>	<b>7,524</b>	<b>9,709</b>
Currency translation difference	30	(28)
<b>Cash and cash equivalents at the end of the financial period</b>	<b>12,050</b>	<b>9,320</b>

The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Group's Audited Financial Statements for the year ended 31 December 2007 and the accompanying explanatory notes attached to the interim financial report.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008**

**1 Accounting policies and methods of computation**

The interim financial report has been prepared under the historical cost convention except for the revaluation of properties included within property, plant and equipment and investment properties.

The interim financial report is unaudited and has been prepared in compliance with FRS No.134, “Interim Financial Reporting” and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad. It should be read in conjunction with the Group’s most recent audited financial statements for the year ended 31 December 2007.

**2 Changes in accounting policies**

The significant accounting policies adopted are consistent with those adopted in the audited financial statements for the year ended 31 December 2007 except for the adoption of the following applicable new/revised Financial Reporting Standards (“FRS”) and Interpretations effective to the Group for financial year beginning 1 January 2008:

FRS 107	Cash Flow Statements
FRS 112	Income Taxes
FRS 118	Revenue
FRS 120	Accounting for Government Grants and Disclosure of Government Assistance
FRS 134	Interim Financial Reporting
FRS 137	Provisions, Contingent Liabilities and Contingent Assets
Amendment to FRS 121	The Effects of Changes in Foreign Exchange Rates - Net Investment in a Foreign Operation

The adoption of these FRSs does not have significant financial impact on the Group. The principal effects of the change in accounting policies resulting from the adoption of the revised FRS 112 is discussed below:

**FRS 112: Income Taxes**

Prior to 1 January 2008, the Group did not account for unutilised tax reinvestment or other similar tax allowance as a deferred tax asset. The revised FRS 112 requires that entities with unutilised tax reinvestment or other similar tax allowance in excess of the normal capital allowance will have to recognise deferred tax asset to the extent that it is probable that the future taxable profit will be available against which the unutilised reinvestment or other similar tax allowance can be utilised. The adoption of the revised FRS 112 has resulted in a change in accounting policy. This change has been accounted for retrospectively and as disclosed in Note 3, certain comparatives have been restated. The effects on the consolidated balance sheet at 30 September 2008 and income statement for the period ended 30 September 2008 are set out in note 4.

**3 Comparatives**

The following comparative amounts have been restated due to the adoption of the revised FRS:

	<u>Increase/(Decrease)</u>		
<u>At 31 December 2007</u>	<u>Previously stated</u>	<u>FRS 112</u>	<u>Restated</u>
	RM'000	RM'000	RM'000
Retained earnings	49,490	2,320	51,810
Deferred tax liabilities	4,307	(2,320)	1,987

**4 Effect on adopting the revised FRS 112 on the current interim financial statements**

	<u>Increase</u>	<u>Decrease</u>
<u>Balance Sheet</u>	RM'000	RM'000
Retained earnings		(518)
Deferred tax liabilities	518	
<u>Income Statement</u>		
Income tax expense	518	

**5 Audit report qualifications of the preceding annual financial statements**



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

The Auditors had reported without any qualifications on the Group's audited financial statements for the year ended 31 December 2007.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008**

**(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008 (continued)**

6 Seasonality or cyclicity of interim operations

The Group's interim operations are not affected materially by any seasonal or cyclical factors.

7 Unusual items

There were no unusual items that affected the assets, liabilities, equity, net income or cash flows for the period ended 30 September 2008.

8 Changes in estimates of amounts reported in prior interim years of the current financial year or in prior financial year

There were no changes in estimates of amounts reported in the prior interim years of the current financial year or prior financial year.

9 Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the period ended 30 September 2008.

10 Dividends paid

The amount of dividends paid/payable during the current and previous interim periods are as follows:

	30/09/2008	30/09/2007
	RM'000	RM'000
<u>In respect of the financial year ended 31 December</u>		
2008: Interim Dividend of 5 sen gross per share less tax payable on 16-Oct-08	2,774	-
2007: Final Tax-exempt Dividend of 4.5 sen per share paid on 23-Jun-08	3,374	-
2007: Interim Tax-exempt Dividend of 4 sen per share paid on 16-Oct-07	-	2,998
2006: Final Dividend of 5 sen gross per share less tax paid on 22-Jun-07	-	2,737
	6,148	5,735

11 Segmental Reporting

<b>BUSINESS SEGMENTS</b>	Manufacturing	Marketing and distribution	Investment holding	<b>GROUP</b>
<b>PERIOD ENDED 30/09/2008</b>	RM'000	RM'000	RM'000	RM'000
Total Revenue	41,255	166,871	7,794	215,920
Inter-segment revenue	(14,739)	-	(7,354)	(22,093)
External Revenue	26,516	166,871	440	<b>193,827</b>
Segment Results (external)	9,458	6,167	(1,228)	14,397
Unallocated corporate expenses				(899)
Finance costs				(753)
Share of results of associate				1,573
Profit before tax				<b>14,318</b>

<b>BUSINESS SEGMENTS</b>	Manufacturing	Marketing and distribution	Investment holding	<b>GROUP</b>
<b>PERIOD ENDED 30/09/2007</b>	RM'000	RM'000	RM'000	RM'000
Total Revenue	36,026	152,924	1,675	190,625
Inter-segment revenue	(10,823)	-	(1,206)	(12,029)
External Revenue	25,203	152,924	469	<b>178,596</b>
Segment Results (external)	8,366	5,754	(677)	13,443
Unallocated corporate expenses				(1,004)
Finance costs				(470)
Deferred gain on previously disposed subsidiary				1,825
Share of results of associate				938
Profit before tax				<b>14,732</b>



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008 (continued)**

**12 Valuations of Property, Plant & Equipment**

The carrying value of land and buildings is based on a valuation carried out in the year ended 31 December 2004 by independent qualified valuers using the comparison method to reflect the market value that have been brought forward, without amendments from that year's audited financial statements.

**13 Significant Post Balance Sheet Events**

There were no significant events that had arisen subsequent to the end of this current period.

**14 Changes in Group Composition**

On 25th September 2008, the Company further announced in relation to its earlier announcement on 13th August 2008 that it has subscribed an additional 25,000 shares in First SGC Pte Ltd ("FSGC") for consideration of S\$117,720 (approximately RM 282,500) resulting in holding a total of 2.445 million shares. This represents 66% of the issued and paid-up share capital of FSGC which is a newly incorporated private limited company in Singapore, whose principal activity is investment holding. As part of the restructuring exercise, the Company's 25% equity interest in its associated company, Xiamen Maidiken Science and Technology Co Ltd ("XMST") held by its wholly owned subsidiary, Apex Pharmacy International Sdn Bhd has been transferred to FSGC which has concurrently acquired an additional 24% equity interest in XMST for consideration of Renminbi 13.3 million (approximately RM 6.7 million) resulting in a combined total of 49% in the enlarged capital of XMST which effectively increased the Group's effective interest from 25% to 32.34%.

Upon completion of all conditions precedent, the restructuring and investment in XMST was completed on 25th September 2008

As reported in the previous quarter, the Company has subscribed 105,000 ordinary shares in Chastal Marketing Pte Ltd ("CMPL") for cash consideration of S\$105,000 (equivalent to RM 292,000), representing 35% of the issued and paid-up share capital of CMPL on 15th April 2008.

Other than the above, the Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long-term investments, restructuring or discontinuation of operations during the period ended 30 September 2008.

**15 Changes in Contingent liabilities or Contingent assets.**

There were no contingent liabilities or contingent assets of the Group since the end of the last annual balance sheet date except as disclosed in note 29.

**16 Capital Commitments**

Capital commitments of property, plant and equipment not provided for in the financial statements as at 30 September 2008 amounted to RM 3,497,000.

**17 Related Party Transactions**

There were no related party transactions during the period ended 30 September 2008.

**18 Review of Performance**

In the 9 months to September 2008, the Group returned profit before tax of RM 14.3 million on Group revenue of RM 193.8 million. After eliminating non-recurring income of RM 1.8 million relating to the disposal of the Group's retail business in the previous corresponding period, revenue and profit before tax grew by 9% and 11% respectively.

Manufacturing division sales have grown by 14% over the previous period, underpinned by core XEPA products, better exports and marketing efforts. Wholesale and Distribution enjoyed a 9% rise with existing customers providing increased volume, and acquisition of new customers. In Singapore, wholesale and distribution activity continues to grow and add new agency lines. The newly-introduced AVEX range of generic pharmaceuticals now comprises 5 products, of which Gastrovex (generic lansoprazole; a second generation proton pump inhibitor for the treatment of gastric and duodenal ulcers) was particularly well received.

On 25th September 2008, the Company increased its effective investment in Xiamen Maidiken Science & Technology Co Ltd ("XMST"), holding company of Luyan (Fujian) Group, from 25% to 32.34% for consideration of Renminbi 13.3 million (RM 6.7 million). The Company's interest is held solely by way of a 66% equity interest in First SGC Pte Ltd. Luyan (Fujian) Group revenues continue to grow strongly through market growth and aggressive marketing.





**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008 (continued)**

19 Material changes in the profit before tax for the quarter

Profit before tax for the current quarter is RM 5.0 million compared to RM 4.2 million for the second quarter. The 20% increase is due primarily to higher margins from own brand products and increased profit contributions from Luyan Fujian (Group) in China.

20 Commentary

(a) Prospects

Notwithstanding highly unsettled economic conditions, the Board is confident that the Group will meet internal performance expectations for the full year. The Group's portfolio of products is strong in competitively priced essential pharmaceuticals, for which there will always be demand. Barring unforeseen circumstances, the Board expects performance for financial year 2008 to be satisfactory.

(b) Progress to achieve forecast revenue or profit estimate

Not applicable

21 Statement by the Board of Directors' opinion on the achievability of forecast revenue or profit estimate

Not applicable

22 Profit Forecast /Profit Guarantee

Not applicable.

23 Income Tax Expense

	3 MONTHS ENDED		PERIOD ENDED	
	30/09/2008	30/09/2007	30/09/2008	30/09/2007
	RM'000	RM'000	RM'000	RM'000
In respect of current year:				
income tax	1,047	557	3,288	1,965
deferred tax	163	177	(28)	730
others	-	-	-	-
	1,210	734	3,260	2,695
In respect of prior year:				
income tax	(207)	(401)	(208)	(401)
deferred tax	-	-	-	-
	1,003	333	3,052	2,294

24 Sale of Unquoted Investments and/or Properties

There were no sale of unquoted investments and/or properties during the period ended 30 September 2008.

25 Quoted Securities

(a) There were no acquisitions or disposals of quoted securities during the period ended 30 September 2008.

(b) There were no quoted securities held as at 30 September 2008.

26 Status of Corporate Proposals

There were no corporate proposals announced but not completed as at 12th November 2008.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008 (continued)**

27 Group Borrowings and Debt Securities

	AS AT	
	30/09/2008	31/12/2007
	RM'000	RM'000
Short term bank borrowings		
Secured	250	239
Unsecured	7,181	10,609
Total	7,431	10,848
Long term bank borrowings		
Secured	374	538
Unsecured	12,540	14,095
Total	12,914	14,633
Bank borrowings denominated in foreign currency as at 30 September 2008	SGD'000	RM'000
Singapore Dollars	260	624

The Group did not have any non-current debt securities denominated in Ringgit Malaysia or foreign currency as at 30 September 2008.

28 Off Balance Sheet Financial Instruments

- (a) The Group's policy is that all foreign currency transactions are hedged by short-term forward contracts. These are translated to the functional currency of the respective entities of the Group at the rates specified in such forward contracts. The Group enters into these forward contracts to protect the Group from movements in exchange rates.
- (b) The Group does not anticipate any market or credit risks arising from these financial instruments.
- (c) As at 12th November 2008, the Group's outstanding forward foreign exchange contracts to hedge its foreign currency transactions are as follows -

	Contracted amount in foreign currency to the nearest thousand	RM'000 equivalent	Contracted rate	Maturity date	Nature and terms
	USD 87	308	3.54	26-Dec-08	Purchase of goods 1 month
	SGD 136	322	2.37	31-Mar-09	Sale of goods 6 months
	SGD 54	128	2.37	30-Apr-09	Sale of goods 6 months
	Sterling Pound 23	143	6.11	6-Apr-09	Purchase of goods 6 months
		901			

29 Material Litigations

(a) Shah Alam High Court Writ of Summons between APM and SDP and ABIO and SDP

On 17th October 2007, the Company announced that Apex Pharmacy Marketing Sdn Bhd ("APM") and ABio Marketing Sdn Bhd ("ABIO"), both wholly owned subsidiaries of the Company, had filed a Writ of Summons against Sante de Pharma Sdn Bhd ("SDP") for breach of contract in respect of distribution agreements ('Agreements') entered into between APM and SDP and ABIO and SDP.

APM and ABIO are taking legal action against SDP to seek court orders:

- for SDP to pay RM1,247,426.98, this being the total net sum owed to APM and ABIO by SDP pursuant to the Agreements;
- compelling SDP to collect stocks valued at RM838,076.43 currently in the possession of APM and ABIO and to pay APM and ABIO the said sum, failing which APM and ABIO shall seek an order to dispose of the stock to recover the value; and
- damages to be assessed based on estimated loss of profits as a result of the wrongful termination of the Agreements.

APM and ABIO have in addition instituted legal proceedings to restrain SDP or any other party from dealing with or attempting to distribute the products referred to in the said Agreements.



**APEX HEALTHCARE BERHAD (473108-T)**

(Incorporated in Malaysia)

**INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2008  
(THE FIGURES HAVE NOT BEEN AUDITED)**

**NOTES TO THE INTERIM FINANCIAL REPORT FOR THE PERIOD ENDED 30 SEPTEMBER 2008 (continued)**

29 Material Litigations (continued)

(a) Shah Alam High Court Writ of Summons between APM and SDP and ABIO and SDP (continued)

Subsequently on 17th December 2007, SDP has filed a counter claim against APM and ABIO claiming the following:

- against APM, the sum of RM 2,514,740 being the amount allegedly owed by APM to SDP, loss of profit of RM 230,000, loss of reputation and goodwill to be determined by the court, interest, legal costs and other reliefs; and
- against ABIO, the sum of RM 1,420,719 being the amount allegedly owed by ABIO to SDP, loss of profit of RM 120,000, loss of reputation and goodwill to be determined by the court, interest, legal costs and other reliefs.

The Company is of the opinion that the counter claims have no merit, and the Company's legal counsel has taken action to persecute the Company's claims and defend against the counter claims.

The case was heard on 5th November 2008 after which the Court has fixed the next hearing on 29th January 2009 for further clarifications/decision.

(b) Shah Alam High Court Writ of Summons between Memory Tech Sdn Bhd and APM

There has been no change in status from that which has been reported in the previous quarter save that the plaintiff, Memory Tech Sdn Bhd is currently undergoing liquidation. The court has postponed the case management to a later date yet to be fixed whilst the Notice of Indemnity has been fixed for mention on 23rd December 2008.

30 Dividends

(a) The interim dividend of 5 sen gross per share less 26% tax in respect of the financial year ending 31 December 2008 has been paid on 16th October 2008.

(b) The total dividend for the current financial year is 5 sen gross less tax. (Year 2007: Interim tax-exempt dividend of 4 sen per share).

31 Earnings per share

		3 MONTHS ENDED		PERIOD ENDED	
		30/09/2008	30/09/2007	30/09/2008	30/09/2007
<b><u>Basic Earnings per share</u></b>					
Profit after tax	RM'000	3,954	3,921	11,143	12,438
Weighted average number of ordinary shares in issue	'000	74,974	74,974	74,974	74,974
<b>Basic earnings per share</b>	<b>sen</b>	<b>5.27</b>	<b>5.23</b>	<b>14.86</b>	<b>16.59</b>
<b><u>Diluted Earnings per share</u></b>					
Profit after tax	RM'000	3,954	3,921	11,143	12,438
Weighted average number of ordinary shares in issue	'000	74,974	74,974	74,974	74,974
Adjustment for share options	'000	-	-	-	-
Weighted average number of ordinary shares in issue for diluted earnings per share	'000	74,974	74,974	74,974	74,974
<b>Diluted earnings per share</b>	<b>sen</b>	<b>5.27</b>	<b>5.23</b>	<b>14.86</b>	<b>16.59</b>